Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast...
July 24 2017 - 8:00AM
Business Wire
SGN-LIV1A to be Investigated in Combination
with Atezolizumab as Part of Initiative for the Development of
Novel Cancer Immunotherapy Combinations
Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology
company, today announced a clinical collaboration agreement with
Genentech, a member of the Roche Group, for the evaluation of its
investigational antibody-drug conjugate (ADC) SGN-LIV1A in
combination with atezolizumab (TECENTRIQ®) in patients with
metastatic triple-negative breast cancer (TNBC). SGN-LIV1A, one of
four clinical-stage treatments under development by Seattle
Genetics for solid tumors, consists of a LIV-1 targeted monoclonal
antibody linked to the potent cell-killing agent monomethyl
auristatin E (MMAE). Breast cancer is the most common cancer among
women worldwide, with an estimated 1.7 million new cases per year.
About 15 to 20 percent of breast cancers are triple negative, which
means they lack expression of three breast cancer-associated
proteins that serve as key therapeutic targets.
“A key challenge in triple-negative breast cancer, or TNBC, is
the lack of available novel targeted treatments. People with this
disease generally have poor prognoses. Moreover, current therapies
are not curative and only delay disease progression,” said Robert
Lechleider, M.D., Senior Vice President, Clinical Development of
Seattle Genetics. “We have phase 1 data showing that SGN-LIV1A is
active as monotherapy in patients with heavily pretreated,
metastatic TNBC. Now, under this new collaboration, we will
evaluate the potential to expand therapeutic benefit to these
patients through combination therapy with atezolizumab.”
SGN-LIV1A administered in combination with atezolizumab will be
evaluated in a phase 1b/2 clinical study as second-line therapy in
patients with metastatic TNBC who have not been previously treated
with immunotherapy. This randomized, controlled study is
anticipated to enroll up to 45 patients in the treatment arm.
Seattle Genetics and Genentech will test the experimental
combination in MORPHEUS, Roche's Novel Cancer Immunotherapy
Development Platform. MORPHEUS is a phase 1b/2 adaptive platform to
develop combinations of cancer immunotherapies rapidly and
efficiently.
Under the terms of the collaboration agreement, Genentech will
manage the study operations for the phase 1b/2 trial. Seattle
Genetics will retain global development and commercialization
rights to SGN-LIV1A.
About SGN-LIV1A
SGN-LIV1A is a novel investigational ADC targeted to LIV-1
protein utilizing Seattle Genetics’ proprietary ADC technology.
LIV-1 is expressed by most metastatic breast cancers. It has also
been detected in a number of other cancers, including melanoma,
prostate, ovarian, and cervical cancer. SGN-LIV1A consists of a
LIV-1-targeted monoclonal antibody linked to a potent
microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a
protease-cleavable linker, using the same technology as ADCETRIS
(brentuximab vedotin). It is designed to bind to LIV-1 on cancer
cells and release the cell-killing agent into target cells upon
internalization. SGN-LIV1A may also cause antitumor activity
through other mechanisms, including activation of an immune
response.
TECENTRIQ® (atezolizumab) is a registered trademark of
Genentech, a member of the Roche Group.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company that
develops and commercializes novel antibody-based therapies for the
treatment of cancer. The company’s industry-leading antibody-drug
conjugate (ADC) technology harnesses the targeting ability of
antibodies to deliver cell-killing agents directly to cancer cells.
ADCETRIS® (brentuximab vedotin), the company’s lead product, in
collaboration with Takeda Pharmaceutical Company Limited, is the
first in a new class of ADCs commercially available globally in 67
countries for relapsed classical Hodgkin lymphoma and relapsed
systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics
is also advancing enfortumab vedotin, an ADC for metastatic
urothelial cancer, in a planned pivotal trial in collaboration with
Astellas. Headquartered in Bothell, Washington, Seattle Genetics
has a strong pipeline of innovative therapies for blood-related
cancers and solid tumors designed to address significant unmet
medical needs and improve treatment outcomes for patients. The
company has collaborations for its proprietary ADC technology with
a number of companies including AbbVie, Astellas, Bayer, Celldex,
Genentech, GlaxoSmithKline and Pfizer. More information can be
found at www.seattlegenetics.com
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the therapeutic
potential of SGN-LIV1A and its possible benefits and uses, as
monotherapy or in combination with atezolizumab. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the inability of SGN-LIV1A to show sufficient
activity in the clinical setting referenced above and the risk of
adverse events of SGN-LIV1A alone or in combination with
atezolizumab. More information about the risks and uncertainties
faced by Seattle Genetics is contained under the caption “Risk
Factors” included in the company’s Quarterly Report on Form 10-Q
for the quarter ended March 31, 2017 filed with the Securities and
Exchange Commission. Seattle Genetics disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170724005400/en/
Seattle Genetics, Inc.Investors:Peggy Pinkston,
425-527-4160ppinkston@seagen.comorMedia:Kavita V. Shah, Ph.D.,
425-527-4188kshah@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024